Physician profile
Rupalini Rawal-Dhingra
NPI 1588971998
$5,664.66
in general payments reported to CMS, 2019-2025
31 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $263 · 2021: $443 · 2022: $3,393 · 2023: $494 · 2024: $375 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,061.23 | 2022 | |
| Astellas Pharma US INC | $416.37 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $405.41 | 2019-2023 | |
| Therapeuticsmd, INC. | $183.89 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.08 | 2019-2025 | |
| Pfizer INC. | $138.47 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $132.63 | 2021-2025 | |
| Exact Sciences Corporation | $111.96 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $107.52 | 2021-2022 | |
| Phadia US INC. | $85.78 | 2023 | Immunocap |
| Sumitomo Pharma America, INC. | $85.25 | 2023-2025 | Myfembree |
| Minerva Surgical, INC | $79.34 | 2021 | |
| Avion Pharmaceuticals | $76.94 | 2019-2020 | |
| Exeltis, USA INC. | $66.32 | 2019-2025 | Slynd |
| Mylan Pharmaceuticals INC. | $60.32 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $54.25 | 2021-2022 | |
| Coopersurgical, INC. | $43.49 | 2022-2025 | Paragard T 380a |
| Vertical Pharmaceuticals, LLC | $43.39 | 2019 | |
| Organon LLC | $42.41 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $37.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.42 | 2019-2021 | |
| Duchesnay USA Incorporated | $35.38 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $30.39 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $26.33 | 2021 | |
| Agile Therapeutics, INC. | $23.32 | 2021 | |
| Medtronic, INC. | $19.94 | 2025 | Closurefast |
| Urovant Sciences INC | $19.14 | 2021 | |
| Smith+Nephew, INC. | $18.89 | 2023 | Pico 14, Pico 7 |
| Millicent US INC | $15.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.58 | 2019 | |
| Allergan, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupalini Rawal-Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.